Peer-reviewedCC BYKidney medicine
Four Pillars in Type 2 Diabetes and Chronic Kidney Disease G4-G5: Mission Impossible—or Not Too Late to Start?
- 1Nephrology Center, Toranomon Hospital, Tokyo, Japan
- 2Department of Nephrology, Kanazawa Medical University School of Medicine, Ishikawa, Japan
- 3Department of Nephrology and Rheumatology, Kanazawa University, Ishikawa, Japan
Related
- Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease
- Combination finerenone and empagliflozin for chronic kidney disease with type 2 diabetes: a target trial emulation
- Factors associated with chronic kidney disease stage among patients with uncontrolled diabetes and/or hypertension in Northeastern Thailand: a cross-sectional study
- Real-world safety profile of finerenone in patients with type 2 diabetes and chronic kidney disease: a multi-database pharmacovigilance analysis of the FAERS and JADER systems
- Type 2 diabetes, cardiovascular disease and chronic kidney disease in Hungary: multimorbidity and 11-year survival in a nationwide retrospective study
BibTeX
@article{yamanouchi2026four,
title = {{Four Pillars in Type 2 Diabetes and Chronic Kidney Disease G4-G5: Mission Impossible—or Not Too Late to Start?}},
author = {Masayuki Yamanouchi and Naoki Sawa and Kengo Furuichi and Takashi Wada},
journal = {Kidney medicine},
year = {2026},
month = sep,
url = {https://europepmc.org/article/PMC/PMC13673336},
note = {CC BY},
}
RIS
TY - JOUR
TI - Four Pillars in Type 2 Diabetes and Chronic Kidney Disease G4-G5: Mission Impossible—or Not Too Late to Start?
AU - Masayuki Yamanouchi
AU - Naoki Sawa
AU - Kengo Furuichi
AU - Takashi Wada
PY - 2026
DA - 2026/09/07
JO - Kidney medicine
UR - https://europepmc.org/article/PMC/PMC13673336
SN - 2590-0595
ER -